Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/23269| Title: | Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial. | Austin Authors: | Gleeson, Mary;Counsell, Nicholas;Cunningham, David;Lawrie, Anthony;Clifton-Hadley, Laura;Hawkes, Eliza A ;McMillan, Andrew;Ardeshna, Kirit M;Burton, Cathy;Chadwick, Nick;Gambell, Joanna;Smith, Paul;Mouncey, Paul;Pocock, Christopher;Radford, John;Davies, John;Turner, Deborah;Kruger, Anton;Johnson, Peter;Linch, David | Affiliation: | Guy's and St Thomas' NHS Foundation Trust, London, UK Department of Clinical Haematology, Austin Health, Heidelberg, Victoria, Australia Mount Vernon Cancer Centre, Northwood, UK Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia Western General Hospital, Edinburgh, UK Cancer Research UK Centre, Southampton, UK The University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK East Kent Hospitals, Canterbury, UK HMDS, Leeds Teaching Hospitals NHS Trust, Leeds, UK Nottingham City Hospital, Nottingham, UK The Royal Marsden Hospital, London and Surrey, London, UK Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK University College London, London, UK Royal Cornwall Hospital, Truro, UK Torbay Hospital, Torquay, UK The Royal Marsden Hospital, London and Surrey, London, UK University College London, London, UK Eastern Health, Melbourne, Australia |
Issue Date: | Mar-2021 | Date: | 2020-05-20 | Publication information: | British Journal of Haematology 2021; 192(6): 1015-1019 | Abstract: | We compared the International Prognostic Index (IPI), Revised (R)-IPI and age-adjusted (aa)-IPI as prognostic indices for patients with diffuse large B-cell lymphoma (DLBCL) in the UK National Cancer Research Institute (NCRI) R-CHOP 14 versus 21 trial (N = 1080). The R-IPI and aa-IPI showed no marked improvement compared to the IPI for overall and progression-free survival, in terms of model fit or discrimination. Similar results were observed in exploratory analyses incorporating the Grupo Español de Linfomas/Transplante de Médula Ósea (GELTAMO)-IPI, where baseline β2-microglobulin data were available (N = 655). Although our findings support current use of the IPI, a novel prognostic tool to better delineate a high-risk DLBCL group in the rituximab era is needed. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/23269 | DOI: | 10.1111/bjh.16691 | ORCID: | 0000-0001-6915-9878 0000-0002-9988-5528 0000-0002-0376-2559 |
Journal: | British Journal of Haematology | PubMed URL: | 32436212 | Type: | Journal Article | Subjects: | clinical trials diffuse large B-cell lymphoma international prognostic index rituximab |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.